替格瑞洛对STEMI行急诊PCI后心肌血流灌注的影响观察(3)
[3] Niccoli G， Scalone G， Lerman A， et al. Coronary microvascular obstruction in acute myocardial infarction. European Heart Journal， 2016， 37( 13)：1024-1033.
[4] Zhou H， He XY， Zhuang SW， et al. Clinical and procedural predictors of no-ref low in patients with acute myocardial infarction after primary percutaneous coronary intervention. World Journal of Emergency Medicine， 2014， 5(2)：96-102.
[5] 朱永宏， 贾国良， 周妙， 等. 替格瑞洛治疗41 例急性冠状动脉综合征患者的临床疗效. 中国介入心脏病学杂志， 2013， 21(13)：
374-376.
[6] Zhou D， Andersson TB， Grimm SW. Invitro evaluation of potential drug-drug interactions with ticagrelor：cytochrom P450 reaction phenotyping inhibition， induction and differential kinetics. Drug Metab Dispos， 2011， 39(4)：703-710.
[7] Gurbel PA， Bliden KP， Butler K， etal. Responseto ticagrelor in clopidogrel nonresponders and respondersand effect of switching therapies：the RESPOND study. Circulation， 2010， 121(10)：1188-1199.
[8] Armstrong D， Summers C， Ewart L， et al. Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1. Journal of Cardiovascular Pharmacology and Therapeutics， 2014， 19(2)：209-219.
[9] 馬长生. 冠心病介入治疗——技术与策略. 北京：人民卫生出版社， 2004：15-16.
[收稿日期：2019-05-16], http://www.100md.com(王馨 安健)
[4] Zhou H， He XY， Zhuang SW， et al. Clinical and procedural predictors of no-ref low in patients with acute myocardial infarction after primary percutaneous coronary intervention. World Journal of Emergency Medicine， 2014， 5(2)：96-102.
[5] 朱永宏， 贾国良， 周妙， 等. 替格瑞洛治疗41 例急性冠状动脉综合征患者的临床疗效. 中国介入心脏病学杂志， 2013， 21(13)：
374-376.
[6] Zhou D， Andersson TB， Grimm SW. Invitro evaluation of potential drug-drug interactions with ticagrelor：cytochrom P450 reaction phenotyping inhibition， induction and differential kinetics. Drug Metab Dispos， 2011， 39(4)：703-710.
[7] Gurbel PA， Bliden KP， Butler K， etal. Responseto ticagrelor in clopidogrel nonresponders and respondersand effect of switching therapies：the RESPOND study. Circulation， 2010， 121(10)：1188-1199.
[8] Armstrong D， Summers C， Ewart L， et al. Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1. Journal of Cardiovascular Pharmacology and Therapeutics， 2014， 19(2)：209-219.
[9] 馬长生. 冠心病介入治疗——技术与策略. 北京：人民卫生出版社， 2004：15-16.
[收稿日期：2019-05-16], http://www.100md.com(王馨 安健)